The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema

This study (REDUCE EU) is testing a bronchoscopic procedure called Endobronchial Thermal Liquid Ablation (ETLA) — a minimally invasive lung treatment delivered through a breathing tube — to reduce the size of overinflated lung areas in patients with severe emphysema (a type of advanced COPD where air becomes trapped in the lungs). **You may be eligible if...** - You are 40 or older with a confirmed COPD diagnosis - Breathing tests show your lung function is between 20–49% of normal, with significant air trapping and overinflation - You can walk at least 140 meters in a 6-minute walk test - You have shortness of breath even with activity - You have been on optimized COPD medications and have not smoked for at least 3 months - You are doing regular physical exercise beyond daily activities **You may NOT be eligible if...** - You have recently had a COPD flare-up or lung infection - You are a current smoker - Your lung function is outside the specified range - You have certain other lung or cardiovascular conditions Talk to your doctor to see if this trial is right for you.